News

Perifosine inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway and works by interfering with membranes of cancer cells thereby inhibiting Akt signaling which then affects cell death,

PLX3397 is an oral, selective inhibitor that down-modulates two key cell types, macrophages and mast cells, that are thought to mediate the progression of Hodgkin lymphoma tumours. The

The European Medicines Agency (EMA) has also validated a Marketing Authorisation Application (MAA) for dapagliflozin. The Prescription Drug User Fee Act (PDUFA) date the FDA is aiming for

The objective of the collaboration is to promote new drug development wherein HUYA will assist in the evaluation of research and development projects conducted by pharmaceutical enterprises residing

Transferrin, a protein found in human blood, binds to and transports iron in the bloodstream from and to cells. Transferrin is also studied for pharmaceutical applications as a

Based on the company’s proprietary revolutionary catalyst technology, the new plant will be used to develop new types of catalysts as well as improve processes for catalyst production.

Simcere Pharma has posted a net loss of RMB58.7m ($8.89m) for the fourth quarter of 2010, compared to a loss of RMB75.42m for the same period in 2009.

Additionally, Pyott will also continue to serve the company in his current roles as chairman of the board and CEO. Additionally, the new structure will allow Mr Pyott

Insys utilizes proprietary technologies to develop product candidates that address the clinical shortcomings of existing commercial products. Insys CEO Michael Babich said this is a tremendous achievement for